Kerastem completes enrolment for Phase II trial for early stage hair loss

Cytori Therapeutics' licensee Kerastem Technologies has completed the enrolment stage of STYLE, a Phase II clinical trial investigating early stage hair loss patterns in men and women.

STYLE is a randomised, blinded, and controlled investigation of Kerastem therapy. A total of four trial sites saw enrolment of 70 patients in the US.

The primary endpoint of STYLE is safety and tolerability at six months, while subjects will be monitored for a total of 12 months. Participats will receive one of four treatment arms.

Cytori's president and CEO Dr. Marc H. Hedrick said: “Cytori Cell Therapy is a broadly applicable cell therapeutic platform used now in multiple mid and late stage clinical trials in the US, Japan and Europe. Our partner Kerastem is focused on developing Cytori technology for men and women with alopecia.

“Early proof of concept clinical data has shown promise and Kerastem expects a read out from the trial in approximately one year. This therapy if approved could create a significant value for our stockholders.”

Outside of the US, Kerastem is actively involved in market development. Its therapy is currently being offered at a number of clinics in Europe and Japan.

Kerastem Technologies is a private company owned by Bimini Technologies, and holds global rights to commercialise Cytori Cell Therapy for alopecia and hair related indications.